Fifteen new drugs including the Ozempic will be included in Medicare's next round of price negotiation with drug makers, the Biden administration announced Friday.

Ozempic, used to treat Type 2 diabetes and obesity, is manufactured by Novo Nordisk.

Medicare spent $14.4 billion the company's Ozempic and similar drugs Wegovy and Rybelsus from November 2023 to October 2024. They were used by nearly 2.3 million enrollees during that period, according to CNN. 

Ozempic cost at least $1,000 a month without insurance. 

Some of the drugs besides Ozempic that will undergo price negotiations include calquence which is used for cancer treatment, the antipsychotic drug Vraylar and otezla, which is used to treat psoriatic arthritis.

The new negotiated prices will not be in effect until 2027, according to NBC News.

The drugmakers will get a little over one month to agree to participate in negotiations, or they could face tax penalties.

"We have a chance to negotiate a better deal for the American people," Department of Health and Human Services Secretary Xavier Becerra said. "This is a big deal. Some folks have to cut their pills in half or skip a dose in their prescription so that they can make their prescription last longer."